Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -23.24% is 130% below its 5-year average of -10.09%, near the high end of its 5-year range (-84.91%–2.71%).
12.57% below its 12-month average of -20.65%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -13.57%.
EBITDA MARGIN
-23.24%
EBITDA MARGIN AVG TTM
-20.65%
EBITDA MARGIN AVG 3Y
-13.52%
EBITDA MARGIN AVG 5Y
-10.09%
EBITDA MARGIN AVG 10Y
-6.17%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-12.57%
CURRENT VS 3Y AVG
-71.91%
CURRENT VS 5Y AVG
-130.37%
CURRENT VS 10Y AVG
-276.80%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Cosmos Health Inc.
Market Cap
$18.82M
EBITDA Margin
-23.24%
TTM Avg
-20.65%
3Y Avg
-13.52%
5Y Avg
-10.09%
Market Cap
$16.58M
EBITDA Margin
-82.81%
TTM Avg
-187.23%
3Y Avg
-342.47%
5Y Avg
-369.32%
Market Cap
$16.54M
EBITDA Margin
-579.88%
TTM Avg
-374.35%
3Y Avg
-344.55%
5Y Avg
-411.92%
Market Cap
$16.22M
EBITDA Margin
-13679.31%
TTM Avg
-8051.39%
3Y Avg
-4553.85%
5Y Avg
-5076.49%
Market Cap
$15.91M
EBITDA Margin
-14633.33%
TTM Avg
-7486.14%
3Y Avg
-4543.27%
5Y Avg
-3157.51%
Market Cap
$21.90M
EBITDA Margin
-7.62%
TTM Avg
-5.66%
3Y Avg
-2.78%
5Y Avg
-31.67%
Market Cap
$15.30M
EBITDA Margin
-468.17%
TTM Avg
-602.06%
3Y Avg
-602.06%
5Y Avg
-23374.02%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cosmos Health Inc. (COSM) | $18.82M | -23.24% | -20.65% | -13.52% | -10.09% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.77M | N/A | N/A | N/A | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $20.93M | N/A | N/A | N/A | N/A |
| Bionano Genomics, Inc. (BNGO)vs › | $16.58M | -82.81% | -187.23% | -342.47% | -369.32% |
| Dyadic International, Inc. (DYAI)vs › | $16.54M | -579.88% | -374.35% | -344.55% | -411.92% |
| BioCardia, Inc. (BCDA)vs › | $16.22M | -13679.31% | -8051.39% | -4553.85% | -5076.49% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.91M | -14633.33% | -7486.14% | -4543.27% | -3157.51% |
| Aytu BioPharma, Inc. (AYTU)vs › | $21.90M | -7.62% | -5.66% | -2.78% | -31.67% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | -468.17% | -602.06% | -602.06% | -23374.02% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.20M | -29916.57% | -29916.57% | -29916.57% | -29916.57% |
Gross Margin
10.3%
EBITDA Margin
-23.2%
Operating Margin
-24.6%
Net Margin
-33.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -13.57% |
| 2026-03-31 | -10.24% |
| 2025-12-31 | -55.46% |
| 2025-09-30 | -8.42% |
| 2025-06-30 | -15.54% |
| 2025-03-31 | -3.74% |
| 2024-12-31 | -60.84% |
| 2024-09-30 | -15.60% |
| 2024-06-30 | -16.57% |
| 2024-03-31 | -10.40% |
| 2023-12-31 | -84.91% |
| 2023-09-30 | -21.59% |
| 2023-06-30 | -19.51% |
| 2023-03-31 | -20.52% |
| 2022-09-30 | -1.92% |
| 2022-06-30 | 0.26% |
| 2022-03-31 | 2.71% |
| 2021-12-31 | -2.38% |
| 2021-09-30 | -5.93% |
| 2021-06-30 | -8.54% |
| 2021-03-31 | -13.98% |
| 2020-12-31 | 3.20% |
| 2020-09-30 | 8.14% |
| 2020-06-30 | 8.56% |
| 2020-03-31 | 2.73% |
| 2019-12-31 | 5.25% |
| 2019-09-30 | 0.54% |
| 2019-06-30 | -4.42% |
| 2019-03-31 | -0.49% |
| 2018-12-31 | -13.19% |
| 2018-09-30 | 0.59% |
| 2018-06-30 | -0.80% |
| 2018-03-31 | -1.18% |
| 2017-12-31 | -20.50% |
| 2017-09-30 | 0.24% |
| 2017-06-30 | -12.94% |
| 2017-03-31 | -48.10% |
| 2016-12-31 | -1.27% |
| 2016-09-30 | -2.02% |
| 2016-06-30 | -9.00% |
| 2016-03-31 | -3.29% |
| 2014-12-31 | 151.29% |
| 2014-09-30 | 96.66% |
| 2014-06-30 | 86.37% |
| 2014-03-31 | 90.63% |
| 2013-12-31 | 95.50% |
